KRAS and cancer: However, even in KRAS wild‐type patients, a germline variant in the let‐7 miRNA binding site of the KRAS 3′ UTR (rs61764370, KRAS‐variant) has been shown to increase risk for certain types of cancers and to predict treatment outcomes.